Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2962 90Y- and/or 177Lu-DOTATOC Re-Challenge in Patients with Progressive Neuroendocrine Tumors

Introduction: Most patients treated with PRRT will eventually progress. Previous studies indicated that repeated PRRT is feasible and promising.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Aberle S

Authors: Aberle S, Benz M, Grokovski R, Christ E, Nicolas G,

Keywords: PRRT, Re-challenge, 90Y-DOTATOC, 177Lu-DOTATOC, neuroendocrine tumor,

#2923 Interim Analysis of Prospective Evaluation of the Management of Sporadic Nonfunctioning Asymptomatic Pancreatic Neuroendocrine Neoplasms ≤ 2 cm (ASPEN Study)

Introduction: Guidelines recommend a watchful strategy for small, incidental, nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNEN).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Partelli S

Authors: Partelli S, Zerbi A, Massironi S, Jin-Young J, Landoni L,

Keywords: small neuroendocrine pancreatic tumors, surveillance, surgery, follow-up,

#2824 Patient and Nurse Satisfaction with the New Lanreotide Autogel Pre-Filled Syringe in Neuroendocrine Tumors (NET): A Prospective Study (SONATE)

Introduction: A new syringe (NS) for the delivery of lanreotide autogel was approved in Oct 2018 in France. The NS includes updated features (larger flanges, more robust plunger) intended to ease the injection.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Walter T, Eskenazi M, Rama N, Gueguen D, Mir O,

Keywords: neuroendocrine tumors, lanreotide, nursing, patient-reported outcomes,

#2820 Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma

Introduction: Esthesioneuroblastoma (ENB) is a rare malignancy with limited therapeutic options when unresectable or metastatic. The overexpression of cell-surface somatostatin receptors in ENB is a potential molecular target making it amenable to peptide receptor radionuclide therapy (PRRT). High-level evidence supporting PRRT has been published for unresectable gastroenteropancreatic neuroendocrine tumours; however, data is limited for PRRT efficacy for ENB.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Kamel Hasan O

Authors: Kamel Hasan O, Ravi Kumar A, Kong G, Grozinsky-Glasberg S, Hicks R,

Keywords: esthesioneuroblastoma, peptide receptor radionuclide therapy, lutetium-177 dotatate,

#2811 Improving Diagnosis Times as Part of the Transformation of the South Wales NET Service

Introduction: Transformation of the South Wales NET service in late 2017 introduced new specialised staff, gastroenterology-led clinics and improved MDTs with a particular emphasis on educating referring specialties. This has led to improved overall patient experience, satisfaction and quality of life. NETs are recognised world-wide for their lengthy diagnosis times.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Amin K

Authors: Amin K, Gruber M, Shayan-Arani H, Taylor R, Powell C,

Keywords: neuroendocrine, tumours, diagnosis, survival, gastroenterology, surgery, new service, nets, south wales, midgut, pancreatic, paraganglioma, incidental,